We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Urinary Dipstick Tested for Intestinal Schistosomiasis

By LabMedica International staff writers
Posted on 18 Mar 2013
The Urine Circulating Cathodic Antigen (CCA) dipstick has been tested as a substitute for microscopy for mapping and point-of-care (POC) diagnosis of intestinal schistosomiasis.

The diagnostic performance of a commercially available urinary CCA dipstick test has been compared to that of fecal microscopy for POC diagnosis in preschool-aged children. More...


Scientists at the Liverpool School of Tropical Medicine (Liverpool, UK) working with colleagues in Uganda recruited a total of 925 children whose mean age was 2.8 years, from six lakeshore villages representative of high, moderate and low levels of disease transmission. At baseline, all children were tested for intestinal schistosomiasis by microscopic examination of duplicate Kato-Katz smears prepared from a single stool; by antigen detection with the urine CCA immunochromatographic dipstick; and by serology with a commercially available enzyme-linked immunosorbent assay (ELISA; IVD Inc.; Carlsbad, CA, USA) that measures host antibody titers to soluble egg antigens.

In low, moderate, and high transmission settings, the observed prevalence of egg-patent schistosomiasis according to fecal microscopy was 7.2%, 16.9% and 38.8% before treatment, and 6.9%, 25.0% and 47.5% one year after treatment. In low, moderate, and high transmission settings, the observed prevalence of Schistosoma mansoni infections according to CCA dipsticks (Rapid Medical Diagnostics; Pretoria, Republic of South Africa) was 45.9%, 45.4% and 56.1% before treatment, and 39.6%, 44.8% and 55.9% one year after treatment, respectively. Most of the positive diagnoses were single positive reactions, with few double and triple positive reaction recorded.

According to the ELISA results, the observed prevalence of S. mansoni infections was 36.0%, 49.0%, and 81.6% before treatment and 18.4%, 52.8%, and 92.0% one year after treatment, in low, moderate, and high transmission settings, respectively. As a point-of-care diagnosis, the urine CCA dipstick achieved sensitivity values ranging from 52.5% to 63.2% and specificity values of 57.7% to 75.6%. Fecal microscopy achieved very high specificities of greater than 87%, but sensitivities as low as 16.7% in the low transmission setting.

The authors concluded that the CCA is a viable alternative for diagnosis of S. mansoni infections in preschool-aged children, particularly in low transmission settings or in areas where treatment has reduced prevalence to low levels. The urine CCA commercial test was proven more sensitive than fecal smears for mapping proposes, and it was as reliable as fecal microscopy for point-of-care diagnosis. The study was published on January 24, 2013, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:
Liverpool School of Tropical Medicine
IVD Inc.
Rapid Medical Diagnostics


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Pan-Cancer Panel
TruSight Oncology 500
New
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.